This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Name: This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
License: Public Domain

Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology · clinicaltrials

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

acute lymphobkastic leukemia, b cell lymphoma

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Record · ID 67863 · SHA-256 e5bfa50054351e7a
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.